Category - Executive Moves

Executive Moves

Cantor expands healthcare and biotech research

Cantor Fitzgerald has expanded its healthcare equity research team with the addition of Bill Tanner as a senior research analyst covering biotechnology and Steven Halper as a senior research analyst covering healthcare...

December 16, 2016

Executive Moves

Aurinia Pharma names Jeffry Randal to board

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Lorin Jeffry Randall to its board and chairman of the audit committee.

December 13, 2016

Executive Moves

3DS names Helen Stevenson to board, Ian Smith to CSAB

3D Signatures (TSX-V:DXD) named Helen Stevenson to the board and Ian Smith, who is stepping down from the board, to the clinical and scientific advisory board (CSAB).

December 9, 2016

Executive Moves

Nigel Terrett joins 3DS business advisory board

3D Signatures (TSX-V:DXD) has appointed Nigel Terrett to 3DS's business advisory board to provide the company with strategic insight and guidance related to commercial lab partnerships and information technology...

December 5, 2016

Executive Moves

Jeff Sacher joins Aegis to lead firm’s healthcare banking

Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served...

November 8, 2016

Executive Moves

Microbix names Jim Currie as CFO

Microbix Biosystems (TSX:MBX) appointed Jim Currie as CFO, succeeding Charles Wallace, who is retiring at the end of the year.Mr. Currie was most recently CFO of SMTC, a global electronics manufacturing services company...

November 1, 2016

Executive Moves

Jason Flowerday named CEO of 3D Signatures

3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board."Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive...

September 27, 2016

Executive Moves

Stereotaxis strengthens financial position, expands Board of Directors

Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.The...

September 27, 2016

Executive Moves

pSivida names Nancy Lurker as CEO

pSivida (NASDAQ:PSDV) has appointed Nancy Lurker as president, CEO and a member of the board, succeeding Paul Ashton, who has resigned to pursue other interests.Ms. Lurker, a seasoned healthcare executive, brings strong...

September 15, 2016

Executive Moves

Wendy Naimark joins Interface Biologics as VP of R&D

Closely-held Interface Biologics (IBI) has appointed Wendy Naimark as VP of research & development.Wendy joins IBI after five years as senior director, clinical and preclinical sciences at 480 Medical, an early...

September 13, 2016

Category - Executive Moves

Cantor expands healthcare and biotech research

Aurinia Pharma names Jeffry Randal to board

3DS names Helen Stevenson to board, Ian Smith to CSAB

Nigel Terrett joins 3DS business advisory board

Jeff Sacher joins Aegis to lead firm’s healthcare banking

Microbix names Jim Currie as CFO

Jason Flowerday named CEO of 3D Signatures

Stereotaxis strengthens financial position, expands Board of Directors

pSivida names Nancy Lurker as CEO

Wendy Naimark joins Interface Biologics as VP of R&D

General

More